Arcus Biosciences, Inc. (RCUS) earnings date
Feb 23, 2027, after close estimated
Estimated from the company's SEC filing cadence. The company has not confirmed it. Companies usually announce two to four weeks ahead.
- Fiscal period
- Q4 FY2026
- Confidence
- 45% chance of landing within a day
- Source
- Filing history on EDGAR
- Last checked
- 2026-11-19
Read by software from public filings and company announcements. Can be wrong. Verify with the company or the SEC. Not investment advice.
How this company behaves
| Announces its report date | Not enough announcements on file yet to say |
| Reports after the quarter ends | 36 days, typically, give or take 10 (last 8 releases) |
Last 8 releases
| Period | Released | Timing | Days after period end | Filing |
|---|---|---|---|---|
| Q3 FY2026 | Wed, Nov 4, 2026 | after close | 35 | 8-K |
| Q2 FY2026 | Wed, Aug 5, 2026 | after close | 36 | 8-K |
| Q1 FY2026 | Tue, May 5, 2026 | after close | 35 | 8-K |
| Q4 FY2025 | Wed, Feb 25, 2026 | after close | 56 | 8-K |
| Q3 FY2025 | Tue, Oct 28, 2025 | after close | 28 | 8-K |
| Q2 FY2025 | Wed, Aug 6, 2025 | after close | 37 | 8-K |
| Q1 FY2025 | Tue, May 6, 2025 | after close | 36 | 8-K |
| Q4 FY2024 | Tue, Feb 25, 2025 | after close | 56 | 8-K |
What they guided beta
| Q3 FY2026 | "Enrollment in PEAK-1, the Phase 3 study of casdatifan plus cabozantinib in the second line, is expected to complete in the next two to three months, and PEAK-20, Arcus's first-line Phase 3 study evaluating casdatifan plus ipilimumab and nivolumab, is on track to initiate by year-end 2026" exhibit |
| Q3 FY2026 | "Multiple additional data readouts, including more mature progression-free survival (PFS) and overall survival (OS) data from the second-line and first-line cohorts of ARC-20, are expected in 2027" exhibit |
| Q3 FY2026 | "Initiation of PEAK-20, a Phase 3 study evaluating casdatifan plus ipilimumab and nivolumab, is expected in the fourth quarter of 2026." exhibit |
| Q3 FY2026 | "Arcus expects to initiate a new cohort evaluating casdatifan in combination with anti-PD-1 and axitinib in the first half of 2027." exhibit |
| Q3 FY2026 | "Upcoming Data Expected in 2027:" exhibit |
| Q2 FY2026 | "Multiple ARC-20 data readouts for casdatifan across lines of therapy are expected in the second half of 2026, including initial efficacy data for casdatifan plus zimberelimab in first-line, progression-free survival (PFS) data for casdatifan plus cabozantinib in second-line and overall survival data for casdatifan monotherapy in late-line ccRCC" exhibit |
| Q2 FY2026 | "Arcus has also executed one additional clinical collaboration agreement to evaluate a casdatifan combination with another anti-PD-x/VEGF bispecific antibody in first-line ccRCC, which is expected to initiate in the fourth quarter of 2026." exhibit |
| Q2 FY2026 | "TKI-free (casdatifan plus IO/IO): The cohort evaluating casdatifan plus zimberelimab (anti-PD-1) and ipilimumab (anti-CTLA-4) in the ARC-20 study is currently enrolling, with the purpose of supporting Arcus’s first registrational Phase 3 study, PEAK-20, evaluating casdatifan plus nivolumab plus ipilimumab in the first-line setting, which is expected to initiate by year-end 2026." exhibit |
| Q2 FY2026 | "TKI-containing (casdatifan plus IO/TKI): A casdatifan-based regimen inclusive of the well-established TKI axitinib, for those circumstances where physicians prefer to have a TKI-inclusive therapy, with an ARC-20 cohort expected to begin in the fourth quarter of 2026." exhibit |
| Q2 FY2026 | "IO-Experienced (second-line) ccRCC: Enrollment in PEAK-1, the global Phase 3 study evaluating casdatifan plus cabozantinib versus cabozantinib alone in IO-experienced metastatic ccRCC, is accelerating, and Arcus remains on track to complete enrollment by year-end 2026." exhibit |
Get this as JSON
curl -H "X-API-Key: vt_live_..." https://api.veritasdata.dev/v1/next/RCUS
# how far back the record goes for this company
curl -H "X-API-Key: vt_live_..." https://api.veritasdata.dev/v1/coverage/RCUS
Put this date on your page
A badge that stays current. It links back to this page and needs no key. Embed it unmodified, with its link to this page intact: the badge is too small to carry the notice below, so the page it links to does.
Read by software from public filings and company announcements. Can be wrong. Verify with the company or the SEC. Not investment advice.
HTML
<a href="https://veritasdata.dev/company/RCUS/"><img src="https://veritasdata.dev/embed/RCUS.svg" alt="RCUS earnings date" width="240" height="56"></a>
Markdown
[](https://veritasdata.dev/company/RCUS/)
Script
<script async src="https://veritasdata.dev/embed/RCUS.js"></script>
Get a free key: 100 calls, every company
Sign in with GitHub or Google. The key works on every endpoint and in the MCP server.
curl -H "X-API-Key: vt_live_..." "https://api.veritasdata.dev/v1/next/RCUS"
Dates come only from SEC EDGAR and company announcements. Nothing here is investment advice.